Recruiting studies: Relapsed Refractory Marginal Zone Lymphoma R R Mzl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05846750 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Len
Phase 3 · 169 location(s) · Regeneron Pharmaceuticals · NCT06149286 Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treat
Phase 2 · 1 location(s) · University of California, Davis · NCT06905509 Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 · 3 location(s) · Reid Merryman, MD · NCT06563596 Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3 · 48 location(s) · The Lymphoma Academic Research Organisation · NCT06006117

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.